The appearance of scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter A1 (ABCA1) in macrophages and liver implicates these transporters in different stages of reverse cholesterol transport. This review focuses on the role of SR-BI and ABCA1 in reverse cholesterol transport in the context of atherosclerotic lesion development.
Introduction
Atherosclerotic cardiovascular disease is the major cause of morbidity and mortality worldwide [1] . A pathological hallmark of atherosclerosis is the excessive accumulation of cholesterol by macrophages, leading to their conversion to foam cells [2] . Current therapeutic strategies to prevent atherosclerosis are primarily based on the use of statins, inhibitors of de-novo cholesterol synthesis, that decrease serum LDL cholesterol levels [3, 4] . Despite the proven effectiveness of statins and their widespread use, the incidence of cardiovascular disease remains high, indicating an important need for new therapies. While plasma LDL cholesterol levels are positively correlated with atherosclerosis, numerous epidemiological studies have established an inverse correlation between the risk for atherosclerosis and plasma HDL cholesterol levels [5] [6] [7] . Several mechanisms by which HDL inhibits the development and progression of atherosclerosis have been proposed, including reductions in oxidative damage, endothelial dysfunction, and inflammation. The most important atheroprotective function, however, is the HDL-mediated catalysis of reverse cholesterol transport, a process in which HDL receives excess cholesterol from peripheral tissues, including macrophages in the arterial wall, which is subsequently delivered to the liver for biliary excretion. Our understanding of reverse cholesterol transport and the molecular mechanisms that control serum HDL cholesterol levels have been dramatically increased by the discovery of scavenger receptor BI (SR-BI) and ATP-binding cassette transporter A1 (ABCA1). In this review we will focus on the current view of the role of SR-BI and ABCA1 in reverse cholesterol transport and the implications for atherosclerosis.
Scavenger receptor BI and ATP-binding cassette transporter A1
SR-BI is a 509-amino-acid cell surface glycoprotein with a molecular mass of 82 kDa [8, 9] . Its predicted secondary structure comprises two transmembrane and two cytoplasmic domains as well as a large extracellular loop containing several N-glycosylation sites [10] . SR-BI is highly conserved in evolution and is expressed in various mammalian tissues and cells, including brain, kidney, intestine, heart, placenta, macrophages, endothelial cells, smooth muscle cells, and various epithelial cells. The highest expression of SR-BI, however, is in organs with critical roles in cholesterol metabolism (liver) and steroidogenesis (adrenal, ovary, testis) [9, 11, 12] . Distinct binding sites on SR-BI have been implicated in the binding of a wide array of ligands, including anionic phospholipids [13] , advanced glycation end products [14] , apoptotic cells [15] , and native and modified lipoproteins [16] [17] [18] [19] .
Importantly, SR-BI mediates the selective uptake of cholesteryl esters from HDL by cells through a process in which the cholesteryl esters are internalized without the net internalization and degradation of the lipoprotein itself (reviewed in [20] ). The exact cellular mechanisms for selective uptake of cholesteryl esters, however, are largely unknown. SR-BI reconstituted into liposomes mediates high-affinity lipoprotein binding and selective cholesterol uptake, indicating that selective uptake is an intrinsic quality of the receptor that does not require specific cellular structures or compartments [21] . Alternatively, several recent studies have indicated a so-called retro-endocytosis pathway, which involves the holoparticle uptake of HDL followed by re-secretion of cholesteryl ester-poor HDL leading to the net uptake of lipids [22, 23, 24 ] . The relative contribution of each pathway, however, is currently unknown. In addition to its role in the selective uptake of HDL cholesteryl esters, SR-BI stimulates the bi-directional flux of free cholesterol between cells and HDL and the rate of cholesterol efflux from various cell types correlates with the expression of SR-BI [25] [26] [27] .
ABCA1 is a 2261-amino-acid, 240 kDa protein belonging to a large family of conserved transmembrane proteins that use ATP as an energy source that drives the transport of a wide variety of molecules across the plasma membranes of living cells [28] . ABC transporters typically consist of two six-helix transmembrane domains that make up a pathway for the translocation of substrates across membranes and two nucleotide-binding domains that bind ATP and provide the energy for substrate transport [29, 30] . In contrast to SR-BI, which binds mature HDL, ABCA1 interacts preferentially with lipid-poor apoA-I. Binding of apoA-I to the extracellular domain of ABCA1 lipidates apoA-I thereby forming nascent HDL. Lipidation of apoA-I by the transfer of phospholipids and cholesterol has been suggested to reduce its affinity for ABCA1, resulting in the release of the lipidated apoA-I [31] . However, Fitzgerald and colleagues [32 ] recently demonstrated that a mutant form of ABCA1 (W590S), which avidly binds apoA-I but fails to promote lipid efflux to apoA-I, released apoA-I with the same kinetics as wild-type ABCA1, indicating that release of apoA-I from ABCA1 is independent of lipid transfer.
In addition to apoA-I, other apolipoproteins with amphipathic helical motifs, including apoA-II, apoC-I, apoC-II, apoC-III, and apoE, efficiently induce lipid efflux by the same mechanism [32, 33, 34 ] . Details of the molecular interaction between ABCA1 and the amphipathic apolipoprotein acceptors and the mechanism of lipidation are the subject of intensive investigation. According to one model, ABCA1 flips phospholipids to the outer leaflet of the plasma membrane where they are subsequently microsolubilized by apoA-I [35, 36] . By contrast, several lines of evidence suggest that ABCA1 is an apoA-I receptor that upon binding induces the transfer of cholesterol and phospholipids [34, 37, 38] . In addition, a hybrid model has been proposed in which apoA-I first interacts with the lipid bilayer and then through lateral diffusion subsequently forms a complex with ABCA1 [39] . Interestingly, recently Denis et al. [40 ] found that the majority of ABCA1 is a tetramer that binds apoA-I and that the resulting nascent lipoproteins contain at least four molecules of apoA-I. ABCA1 is ubiquitously expressed, with highest expression levels in placenta, fetal tissues, lung, adrenal glands, brain, and liver [41] . In addition, ABCA1 is highly expressed in macrophages where its expression is stimulated by cholesterol loading. The fact that both SR-BI and ABCA1 are expressed in macrophages and liver implicates them in distinctly different steps of reverse cholesterol transport, from the generation of nascent HDL and cholesterol efflux from arterial wall macrophages to the delivery of HDL cholesteryl esters to the liver for excretion into the bile.
Scavenger receptor BI and lipoprotein metabolism
The first direct evidence of the physiological importance of SR-BI in HDL metabolism was obtained from studies of genetically engineered mice. Adenovirus-mediated hepatic overexpression of SR-BI resulted in the virtual disappearance of plasma HDL and a substantial increase in biliary cholesterol [42] . A similar decrease in plasma HDL cholesterol levels was found in transgenic mice overexpressing SR-BI under control of the apoA-I promoter [43] . These studies indicated that SR-BI is important for hepatic HDL metabolism and cholesterol secretion into the bile. Studies using transgenic mice with liver-specific overexpression of SR-BI showed an increased selective uptake of HDL cholesteryl esters by the liver compared with nontransgenic controls [44, 45] . In contrast, mice with an attenuated expression of SR-BI (SR-BIatt mice), due to a mutation in the promoter for SR-BI, displayed reduced hepatic uptake of HDL cholesteryl esters [46] . Conclusive evidence that SR-BI plays an important role in HDL metabolism emerged from studies of SR-BI knockout mice [47, 48] . Complete disruption of SR-BI function resulted in an approximately twofold increase in total plasma cholesterol levels due to the accumulation of abnormally large HDL particles, reflecting impaired delivery of cholesteryl esters to the liver. Strikingly, SR-BI deficiency did not alter hepatic cholesterol (ester) content nor did it affect the expression of key regulators of hepatic cholesterol homeostasis, including HMG-CoA reductase, the LDL receptor, and cholesterol 7a-hydroxylase. However, SR-BI deficiency was associated with impaired biliary cholesterol secretion [49] and attenuated expression of ABCG5 and ABCG8, which are ABC, 'half' transporters that are involved in the transport of lipids from the liver to the bile [50] . Recent studies in which the uptake of cholesteryl esters from HDL was compared to holo-particle uptake in SR-BI knockout and wild-type mice demonstrated that SR-BI is the sole molecule responsible for the selective uptake of cholesteryl esters from HDL [51 ,52 ].
Interestingly, SR-BI has also been implicated in the clearance of apoB-containing lipoproteins, including LDL and VLDL. In vitro, SR-BI recognizes apoBcontaining lipoproteins [15] [16] [17] [18] [19] and apoE [53] [54] [55] [56] , an important ligand for VLDL removal from the circulation. In vivo, transgenic mice overexpressing SR-BI display reduced levels of apoB-containing lipoproteins [44, 57] and are not susceptible to the dietary increase in VLDL and LDL levels upon feeding a high-fat/high-cholesterol diet in a heterozygous LDL receptor knockout back-ground [58] . In addition, adenoviral overexpression of SR-BI reduces VLDL and LDL levels in C57Bl/6 mice [42, 59] and reverses fibrate-induced hypercholesterolemia in apoEÀ/À mice [60] . Conversely, increased levels of LDL cholesterol and apoB protein were observed in LDL receptor knockout mice with attenuated expression of SR-BI on a high-fat/high-cholesterol diet [61] . Furthermore, disruption of the SR-BI gene in apoEÀ/À mice results in an increase in circulating VLDL and LDL levels [48] . These observations all implicate SR-BI in the removal of apoB-containing lipoproteins from the circulation. By contrast, Webb et al. have recently shown that adenoviral overexpression of SR-BI in human apoB transgenic mice [62] and apoEÀ/À mice [63] does not affect circulating VLDL and LDL levels.
Interestingly, our group recently demonstrated that the postprandial triglyceride response after an intragastric fat load is higher in the absence of SR-BI [64 ] . Furthermore, the association of chylomicron-like emulsion particles to freshly isolated hepatocytes is largely reduced in the absence of SR-BI. Thus, chylomicron metabolism is also altered by disruption of SR-BI in mice. Consistent with these data, Pé rez-Martinez and colleagues [65 ] have recently suggested a role for CLA-1, the human homologue of SR-BI, in postprandial lipoprotein metabolism. In addition, several studies on common polymorphisms of CLA-1 have been published [66] [67] [68] [69] [70] demonstrating that some SR-BI variants interfere with the metabolism of lipids, including apoB lipoproteins in humans and that the effects vary according to age and gender. In Figure 1 a schematic illustration summarizing the role of SR-BI in HDL and remnant metabolism is shown.
Reverse cholesterol transport and atherosclerosis Van Eck et al. 309 Figure 1 . Role of scavenger receptor class B type I (SR-BI) in the processing of HDL and remnant lipoproteins by the liver SR-BI mediates the selective uptake of cholesteryl esters from HDL without net degradation of the HDL particle itself followed by the release of cholesteryl ester-poor HDL (left). VLDL and chylomicron (CM) remnants are taken up by the liver via a classical endocytotic pathway, which involves an initial sequestration and capture of step in the space of Disse, followed by internalization via the LDL receptor or the LDL receptor-related protein (LRP1) (middle). Recently, a role for SR-BI in the removal of lipoprotein remnants was also established (right). It may be speculated that SR-BI functions in the initial sequestration and capture of remnants whereby the subsequent internalization is exerted by receptor systems like the LDL receptor or LRP1.
Scavenger receptor BI and atherosclerosis
Several lines of evidence indicate an antiatherogenic role for SR-BI in atherogenesis. Hepatic overexpression of SR-BI protects against the development of atherosclerosis [58, 59, 71] . Interestingly, the expression level of SR-BI is critical for its effect on atherosclerosis susceptibility. If the SR-BI expression level is too high, HDL levels are too low to sustain net cholesterol movement through the reverse cholesterol transport pathway [71] . Conversely, the atheroprotective effects of high HDL levels are lost if the turnover of HDL cholesterol is impaired as a result of a reduction of SR-BI expression. LDL receptor deficient (LDLrÀ/À) mice with an attenuated expression of SR-BI are more susceptible to atherosclerotic lesion development [61] . Furthermore, disruption of SR-BI in wild-type [51 ] as well as in LDLrÀ/À mice [72] results in a highly increased susceptibility to atherosclerotic lesion development. When cross-bred onto the apoE knockout background, SR-BI deficiency leads to severe cardiac dysfunction and premature death [73, 74] . By crossbreeding the SR-BI Â apoE double knockout mice with RAG2 mice, which lack B and T lymphocytes, Karackattu et al. [75 ] recently showed that lymphocytes are not required for the rapid onset of coronary artery disease in the SR-BI Â apoE double knockout mice.
The proatherogenic effects of SR-BI deletion are largely attributed to its effects on the uptake of HDL cholesteryl esters by the liver. However, according to the current understanding that SR-BI removes apoB-containing lipoproteins, disruption of SR-BI can also increase the availability of these atherogenic lipoproteins in the arterial wall. Furthermore, SR-BI is expressed in lipid-laden macrophages in human and murine atherosclerotic lesions [76] [77] [78] . SR-BI might thus also play an important role locally in the arterial wall. Bone marrow transplantation studies have shown that SR-BI on macrophages reduces the development of advanced atherosclerotic lesions in LDLrÀ/À [72, 79 ] and apoEÀ/À mice [80] . In contrast, the development of small fatty streak lesions in LDLrÀ/À mice is facilitated by macrophage SR-BI [79 ] . It thus appears that, depending on the stage of lesion development, SR-BI in macrophages is either proatherogenic or antiatherogenic, indicating a unique dual role for SR-BI in the pathogenesis of atherosclerosis that is illustrated in Figure 2 . The unique dual role is likely a direct effect of the multi-functional and multi-ligand qualities of SR-BI, whichbindsa wide arrayof native andmodified lipoproteins and mediates the bi-directional flux of cholesterol between HDL and cells. Its function in the binding of atherogenic lipoproteins, like native bVLDL and oxidized LDL, is expected to induce foam cell formation, while efflux of intracellular cholesterol to HDL will prevent foam cell formation and thus atherosclerotic lesionx development.
Although the atheroprotective function of SR-BI has been well established in genetically engineered mice, the role of CLA-1 in coronary artery disease in humans is still largely unknown. In female patients with premature coronary artery disease an association was found between a combination of two common variants in exons 5 and 8 of the CLA-1 gene with extreme triglyceride : HDL cholesterol ratios [69] . In addition, Rodríguez-Esparragó n and colleagues [81 ] recently showed an association between the CLA-1 exon 8 gene polymorphism and the risk of coronary artery disease. Furthermore, CLA-1 is expressed in macrophage-rich areas of human carotid atherosclerotic lesions [82] , suggesting that this scavenger receptor might also play an important role locally in atherosclerotic lesion development in the arterial wall in humans. 
ATP-binding cassette transporter A1 and lipoprotein metabolism
The discovery that mutations in the human ABCA1 gene are the underlying molecular defect in HDL deficiency syndromes such as Tangier disease has contributed substantially to our understanding of the function of ABCA1 as a key transporter in reverse cholesterol transport [83] [84] [85] . The importance of ABCA1 in HDL metabolism was further substantiated in genetically engineered mice. Targeted disruption of ABCA1 results in a virtual absence of HDL cholesterol [86] [87] [88] , while ABCA1 overexpression increases HDL levels [89, 90] .
Since mutations in ABCA1 are mechanistically linked to rare recessive HDL deficiency syndromes, it has been speculated that sequence variants of ABCA1 may contribute to differences in plasma HDL cholesterol levels in the general population. Recently, Frikke-Schmidt et al. [91 ,92] reported that at least 10% of individuals in the Copenhagen City Heart Study with low HDL are heterozygous for mutations in ABCA1. This finding is further supported by the data from the population-based Dallas Heart Study and in Canadians with low or high plasma HDL cholesterol levels [93 ] .
According to the classical view of the reverse cholesterol transport pathway, ABCA1 in peripheral cells, including macrophages, was presumed to initiate HDL formation by facilitating the transfer of phospholipids and cholesterol from the plasma membrane to lipid-free apoA-I. However, although total-body ABCA1 deficiency is associated with severe HDL deficiency, specific deletion of ABCA1 in macrophages did not affect circulating HDL cholesterol levels [94, 95] . Furthermore, according to Haghpassand et al. [94] reconstitution of macrophage ABCA1 expression in ABCA1-deficient mice resulted in only a small increase in apoA-I levels and the appearance of a-migrating HDL. The contribution of macrophage ABCA1 to overall plasma HDL levels is thus small. It must be noted that these studies were performed in the presence of a functional SR-BI in the liver. It is thus possible that cholesteryl esters from freshly lipidated HDL were rapidly removed by the liver via SR-BI, thereby underestimating the role of ABCA1 in the formation of HDL in the periphery. However, serious questions were raised about the validity of the widely held reverse cholesterol transport hypothesis. The liver secretes lipid-free and lipid-poor apoA-I [96, 97] and expresses high levels of ABCA1 protein [41, 98, 99] , suggesting that the liver itself might mediate lipidation of HDL proteins. In a study with isolated primary hepatocytes from wild-type and ABCA1-deficient mice, Kiss et al. [100] showed that hepatocyte expression of ABCA1 is central to the lipidation of newly synthesized apoA-I. In agreement, adenoviral overexpression of ABCA1 in livers of wild-type mice increases HDL production, indicating that the liver is an important site for the lipidation of HDL in the circulation [101, 102] . Recent studies from the lab of J.S. Parks [103 ,104] showed that plasma HDL and apoA-I levels are dramatically decreased in mice with a liver-specific deletion of ABCA1. Conversely, crossbreeding of mice that selectively overexpress human ABCA1 in the liver with ABCA1 knockout mice corrected the lipid abnormalities in the ABCA1 knockout mice [105] . Thus the liver indeed seems to play an important role in the lipidation of HDL proteins.
Tangier disease results in extremely low plasma HDL cholesterol levels as a result of ABCA1 dysfunction. Low HDL cholesterol levels are frequently associated with raised fasting or postprandial triglyceride levels. In a small cohort of patients, Kolovou et al. [106] showed that Tangier disease patients display an increased susceptibility to postprandial hypertriglyceridemia. In agreement, Joyce et al. [107] reported that overexpression of human ABCA1 in mice in both liver and macrophages not only induces HDL cholesterol levels, but also results in a marked reduction in VLDL cholesterol levels. Interestingly, Sahoo et al. [108 ] recently showed, using cultured primary murine hepatocytes, that cholesterol efflux to apoA-I reduced the secretion of triglycerides and apoB from wild-type hepatocytes, but not from hepatocytes lacking ABCA1. ABCA1-dependent cholesterol mobilization from hepatocytes to apoA-I for HDL particle formation thus seems to compete for the cholesterol availability for VLDL particle secretion. Previously it has been shown that disruption of ABCA1 in mice does not affect the hepatic cholesterol content or the fecal excretion of sterols [109] . In light of the recent findings on the link between ABCA1-mediated HDL lipidation and VLDL secretion by the liver, the compensatory effects on the hepatic VLDL secretion in ABCA1 knockout mice warrant investigation.
ATP-binding cassette transporter A1 and atherosclerosis
Heterozygotes for mutations in ABCA1 are at significant risk for coronary artery disease and ABCA1 gene variations may contribute to the inter-individual variability in atherosclerosis susceptibility in humans [110] [111] [112] [113] [114] [115] [116] . The cardioprotective effects of ABCA1 have been confirmed in several animal models. Overexpression of ABCA1 in mice increases serum HDL cholesterol levels and reduces susceptibility to atherosclerosis in apoE knockout [117] and C57Bl/6 mice [107] . In atherosclerotic lesions, ABCA1 co-localizes with macrophages, indicating that ABCA1 can also affect lesion development independent of effects on HDL cholesterol levels [99] . Indeed, bone marrow transplantation experiments showed that disruption of ABCA1 in macrophages markedly increases atherosclerotic lesion development [95, 118] . Thus, although ABCA1 in macrophages contributes little to the circulating HDL cholesterol levels, ABCA1-dependent cholesterol efflux is a crucial factor in the prevention of excessive cholesterol accumulation in macrophages of the arterial wall and their transformation into foam cells (Fig. 1) .
Recently, Albrecht et al. [119 ] showed that ABCA1 protein levels are reduced in advanced carotid atherosclerotic lesions. Furthermore, our group [120] has found that overexpression of ABCA1 in macrophages could not prevent the initiation of atherosclerosis, but prevented the progression to advanced atherosclerotic plaques. Macrophage ABCA1 is thus an important determinant for the progression of atherosclerosis from initial fatty streaks into advanced lesions, apparently the stage at which endogenous ABCA1 is downregulated. Stimulation of the expression of macrophage ABCA1 thus presents an attractive therapeutic target for the development of novel therapeutic agents designed to prevent the development of advanced atherosclerotic lesions that lead to coronary or cerebral infarction.
Conclusion
Modulation of SR-BI and ABCA1 expression in liver and macrophages has greatly improved the general understanding of the process of reverse cholesterol transport and the relation between HDL cholesterol levels and atherosclerosis. Importantly, it is not the HDL cholesterol level per se but rather the kinetics of HDL metabolism, in which SR-BI and ABCA1 play a decisive role, which determines the atherosclerotic risk. Furthermore, reverse cholesterol transport should be envisioned as a cycle in which the liver plays an essential role for the generation of nascent HDL by ABCA1 and the continuous regeneration of lipid-poor HDL by SR-BI, thereby ensuring the availability of acceptors for SR-BI and ABCA1mediated cholesterol efflux to maintain cholesterol homeostasis in the periphery (Fig. 3 ).
In addition, the suggested role for hepatic SR-BI in facilitating postprandial lipid metabolism and the finding that ABCA1-dependent nascent HDL formation competes for the cholesterol availability for VLDL particle secretion provide new information that remnant and HDL metabolism are intertwined both at receptor level and intracellularly. Reverse cholesterol transport describes the process in which excess cholesterol from peripheral tissues, including arterial wall macrophages, is transported back to the liver. Reverse cholesterol transport, however, does not solely involve unidirectional transport of cholesterol. It is a continuous cholesterol transport cycle in which the liver plays an essential role for the generation of nascent HDL by ATP-binding cassette transporter A1 (ABCA1) and the continuous regeneration of lipid-poor HDL by scavenger receptor class B type I (SR-BI), thereby ensuring the availability of acceptors for SR-BI and ABCA1-mediated cholesterol efflux to maintain cholesterol homeostasis in the periphery.
